nach oben

Erschienen in:

01.06.2010 | Original Article

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

verfasst von: Adam Dangoor, Paul Lorigan, Ulrich Keilholz, Dirk Schadendorf, Adrian Harris, Christian Ottensmeier, John Smyth, Klaus Hoffmann, Richard Anderson, Martin Cripps, Joerg Schneider, Robert Hawkins

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Safety and cellular immunogenicity of rising doses and varying regimens of a poly-epitope vaccine were evaluated in advanced metastatic melanoma. The vaccine comprised plasmid DNA and recombinant modified vaccinia virus Ankara (MVA) both expressing a string (Mel3) of seven HLA.A2/A1 epitopes from five melanoma antigens.

Methods

Forty-one HLA-A2 positive patients with stage III/IV melanoma were enrolled. Patient groups received one or two doses of DNA.Mel3 followed by escalating doses of MVA.Mel3. Immunisations then continued eight weekly in the absence of disease progression. Epitope-specific CD8+ T cell responses were evaluated using ex-vivo tetramer and IFN-γ ELISPOT assays. Safety and clinical responses were monitored.

Results

Prime-boost DNA/MVA induced Melan-A-specific CD8+ T cell responses in 22/31 (71%) patients detected by tetramer assay. ELISPOT detected a response to at least one epitope in 10/31 (32%) patients. T cell responder rates were <50% with low-dose DNA/MVA, or MVA alone, rising to 91% with high-dose DNA/MVA. Among eight patients showing evidence of clinical benefit—one PR (24 months+), five SD (5 months+) and two mixed responses—seven had associated immune responses. Melan-A-tetramer+ immunity was associated with a median 8-week increase in time-to-progression (P = 0.037) and 71 week increase in survival (P = 0.0002) compared to non-immunity. High-dose vaccine was well tolerated. The only significant toxicities were flu-like symptoms and injection-site reactions.

Conclusions

DNA.Mel3 and MVA.Mel3 in a prime-boost protocol generated high rates of immune response to melanoma antigen epitopes. The treatment was well tolerated and the correlation of immune responses with patient outcomes encourages further investigation.

King M, Spooner D, Rowlands DC (2001) Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of the literature. Clin Oncol (R Coll Radiol) 13:466–469

Itoh K, Platsoucas CD, Balch CM (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168:1419–1441CrossRefPubMed

Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA (1991) Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 146:3674–3681PubMed

Talebi T, Weber JS (2003) Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 13:431–438CrossRefPubMed

Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M et al (2006) Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 6:1305–1318CrossRefPubMed

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915CrossRefPubMed

Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL et al (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14:709–714CrossRefPubMed

Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF et al (2005) Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28:382–388CrossRefPubMed

Zhu J, Martinez J, Huang X, Yang Y (2007) Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619–625CrossRefPubMed

10.

Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D et al (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113:259–266CrossRefPubMed

11.

McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S et al (2003) Enhanced T cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729–735CrossRefPubMed

12.

Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL et al (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168:4391–4398PubMed

13.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

14.

Xu Y, Theobald V, Sung C, DePalma K, Atwater L et al (2008) Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med 6:61CrossRefPubMed

15.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMed

16.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634PubMed

17.

Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745 Epub 2006 Sep 4711CrossRefPubMed

18.

Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS (2002) Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 8:3696–3701PubMed

19.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA et al (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23:8968–8977 Epub 2005 Oct 8963CrossRefPubMed

20.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H et al (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1–15CrossRefPubMed

21.

Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ et al (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397–402CrossRefPubMed

22.

Harrop R, Connolly N, Redchenko I, Valle J, Saunders M et al (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12:3416–3424CrossRefPubMed

23.

Luescher IF, Romero P, Kuznetsov D, Rimoldi D, Coulie P et al (1996) HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. J Biol Chem 271:12463–12471CrossRefPubMed

24.

Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B et al (2005) Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10:285–300PubMed

25.

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G et al (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756–2765PubMed

26.

Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T cell responses in advanced melanoma. J Clin Oncol 21:2342–2348CrossRefPubMed

27.

Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y et al (2007) Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 56:515–526CrossRefPubMed

28.

Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J et al (2006) Phase I study of adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060–5069CrossRefPubMed

29.

Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY et al (2007) Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81:5257–5269CrossRefPubMed

30.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C et al (2007) Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 30:240–250CrossRefPubMed

31.

Emens LA, Jaffee EM (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059–8064CrossRefPubMed

Titel: Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine
verfasst von: Adam Dangoor
Paul Lorigan
Ulrich Keilholz
Dirk Schadendorf
Adrian Harris
Christian Ottensmeier
John Smyth
Klaus Hoffmann
Richard Anderson
Martin Cripps
Joerg Schneider
Robert Hawkins
Publikationsdatum: 01.06.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 6/2010
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0811-7

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment

Circulating tumour-derived microvesicles in plasma of gastric cancer patients

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie